Literature DB >> 1312700

Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.

Y Sameshima1, Y Matsuno, S Hirohashi, Y Shimosato, H Mizoguchi, T Sugimura, M Terada, J Yokota.   

Abstract

To clarify the incidence, timing and pathogenetic significance of p53 gene alterations in the progression of small-cell lung carcinoma (SCLC), 17 primary tumors, 13 metastases and nine cell lines from 27 patients were analysed by a polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. Allelic losses and mutations of the p53 gene were detected in 24 out of 25 informative cases (96%) and 23 out of 27 cases (85%) respectively. Simultaneous losses and mutations were detected in all 16 stage III-IV tumors, while these alterations were detected only in 3 of 6 stage I-II tumors. When allelic losses and/or mutations were detected in the primary tumors, the same alterations were always maintained in the process of metastasis. In three cases, identical p53 alterations were detected among different organ metastases. The mutations detected in five cell lines were also detected in the corresponding original tumors. These results suggest that the alterations of the p53 gene are common and early events, but probably not the first events, in the development of SCLC, and that these alterations are essential for the maintenance of malignant phenotypes in the progression of SCLC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312700

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.

Authors:  X Q Qin; D M Livingston; W G Kaelin; P D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

3.  Pleomorphic carcinoma of the lung arising in a patient with Li-Fraumeni syndrome: report of a case.

Authors:  Tatsuya Kato; Keidai Ishikawa; Masaaki Satoh; Satoshi Kondo; Mitsuhito Kaji
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

4.  Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients.

Authors:  Y Q Li; Z P Pavelic; L J Wang; J S McDonald; L Gleich; E Munck-Wikland; S Dacic; Z Danilovic; L J Pavelic; K M Wilson; J L Gluckman; P J Stambrook
Journal:  Clin Mol Pathol       Date:  1995-10

Review 5.  Mouse models for radiation-induced cancers.

Authors:  Leena Rivina; Michael J Davoren; Robert H Schiestl
Journal:  Mutagenesis       Date:  2016-05-21       Impact factor: 3.000

Review 6.  Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.

Authors:  A K Walch; H F Zitzelsberger; M M Aubele; A E Mattis; M Bauchinger; S Candidus; H W Präuer; M Werner; H Höfler
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

Review 7.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

8.  Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data.

Authors:  D Lohmann; B Pütz; U Reich; J Böhm; H Präuer; H Höfler
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

9.  A gene-alteration profile of human lung cancer cell lines.

Authors:  Raquel Blanco; Reika Iwakawa; Moying Tang; Takashi Kohno; Barbara Angulo; Ruben Pio; Luis M Montuenga; John D Minna; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2009-08       Impact factor: 4.878

10.  Biomolecular markers in cancer of the tongue.

Authors:  Daris Ferrari; Carla Codecà; Jessica Fiore; Laura Moneghini; Silvano Bosari; Paolo Foa
Journal:  J Oncol       Date:  2009-08-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.